A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

The results square up with those produced by Supernus’ Qelbree, “which showed a ... given its novel mechanism of action and strong efficacy data to back it up. But the treatment was never ...

The new label further elaborates and differentiates Qelbree's mechanism of action as a novel nonstimulant, reinforcing its multimodal pharmacodynamic profile and highlighting its unique partial ...

Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for ...

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases, announced that the US Food and Drug Administration ...

The new information in Section 12.2 of the label details Qelbree's partial agonist activity at the ... This multimodal pharmacodynamic profile is thought to contribute to the drug's mechanism of ...

Qelbree is the first ADHD treatment to meet its post marketing requirement and receive labeling approval following the 2019 FDA guidance on Clinical Lactation Studies 1 ROCKVILLE, Md., Jan. 27, 2025 ...

The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Additionally, the updated label now includes new lactation data for ...